ASCO 2018

Roche at ASCO 2018

ASCO is the world’s most important oncology congress. More than 32,000 oncology professionals from all over the world and from different specialities meet in Chicago to discuss treatment modalities, new therapies and latest research findings.

Daily reports from ASCO 2018 by Springer Healthcare

Daily reports from the first four days of ASCO 2018, the largest clinical oncology conference in the world. Read about some of the most important information released during the conference. Read more

Presentations

PDF

Jun 05, 2018 | Lung Cancer ASCO 2018 Lung Cancer

IMpower150: Overall Survival Analysis of a Randomized Phase III Study of ▼Atezolizumab + Chemotherapy ± Bevacizumab vs Chemotherapy + Bevacizumab in 1L Nonsquamous NSCLC

PDF

Jun 05, 2018 | Lung Cancer ASCO 2018 Lung Cancer

IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of ▼Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel Vs Carboplatin + Nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC

PDF

Jun 02, 2018 | Lung Cancer ASCO 2018 Lung Cancer

Safety and clinical activity results from a Phase 1b study of ▼alectinib plus ▼atezolizumab in ALK+ advanced NSCLC

Posters

PDF

Jun 02, 2018 | Solid Tumours ASCO 2018 Solid Tumours

Phase 1 study of Entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors

PDF

Jun 02, 2018 | Breast Cancer ASCO 2018 Breast Cancer

IPATunity130: a pivotal randomized phase III trial evaluating ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered advanced triple-negative or hormone receptor-positive HER2-negative breast cancer

PDF

Jun 02, 2018 | Breast Cancer ASCO 2018 Breast Cancer

IMpassion132: a double-blind randomized phase III trial evaluating chemotherapy with or without ▼atezolizumab for early progressing locally advanced/metastatic triple-negative breast cancer

Roche at ASCO 2018

Daily reports from ASCO 2018 by Springer Healthcare

IMpower150: Overall Survival Analysis of a Randomized Phase III Study of ▼Atezolizumab + Chemotherapy ± Bevacizumab vs Chemotherapy + Bevacizumab in 1L Nonsquamous NSCLC

IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of ▼Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel Vs Carboplatin + Nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC

Safety and clinical activity results from a Phase 1b study of ▼alectinib plus ▼atezolizumab in ALK+ advanced NSCLC

Patient-Reported Outcomes in IMmotion151: ▼Atezolizumab Plus Bevacizumab vs Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma

Randomized phase 2 trial of polatuzumab vedotin with bendamustine and ▼rituximab in relapsed/refractory FL and DLBCL

High, durable minimal residual disease (MRD) negativity with ▼venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from the phase 3 MURANO study

Overall survival update of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Prospective Clinical Evaluation of Blood-Based Tumor Mutational Burden as a Predictive Biomarker for ▼Atezolizumab in 1L NSCLC: Interim B-F1RST Results

Application of a real world endpoint to identify and characterize genetic profiles of patients with poor prognosis in advanced non-small-cell lung cancer (aNSCLC)

Association of High Tissue Tumor Mutational Burden (TMB) and ▼Atezolizumab Efficacy Across Multiple Tumor Types

ASCO 2018 Oral presentation: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026

ASCO 2018 Oral presentation: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567

ASCO 2018 video: Prof. D. Ross Camidge describing the updated efficacy and safety data from the global phase III ALEX study of ▼alectinib (AL) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC

Phase 1 study of Entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors

IPATunity130: a pivotal randomized phase III trial evaluating ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered advanced triple-negative or hormone receptor-positive HER2-negative breast cancer

IMpassion132: a double-blind randomized phase III trial evaluating chemotherapy with or without ▼atezolizumab for early progressing locally advanced/metastatic triple-negative breast cancer

Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (MBC) and CNS metastases (CNS mets)

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC)

▼Atezolizumab (Atezo) in Special Populations: Analyses From an Expanded Access Program (EAP) in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma (mUC)

▼Atezolizumab in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer: long-term efficacy from Ph II study IMvigor210

Updated efficacy and safety data from the global phase III ALEX study of ▼alectinib (AL) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC

Pooled Overall Survival and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of ▼Alectinib in ALK-positive Non-Small Cell Lung Cancer (NSCLC)

Patient-reported outcomes in the randomized, Phase III IMpower150 study of ▼atezolizumab + chemotherapy ± bevacizumab vs chemotherapy + bevacizumab in 1L nonsquamous metastatic NSCLC

Neoadjuvant ▼Atezolizumab in Resectable Non-Small Cell Lung Cancer: Interim Analysis Results From of a Multicenter Study (LCMC3)

MORPHEUS: a Phase Ib/II Multi-Trial Platform Evaluating the Safety and Efficacy of Cancer Immunotherapy–Based Combinations in Patients With Non-Small Cell Lung Cancer (MORPHEUS-Lung)

Safety and Clinical Activity of ▼Atezolizumab + Bevacizumab in a Phase Ib Study in First-Line Hepatocellular Carcinoma

MORPHEUS: a Phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with gastric or pancreatic cancer

IMbrave150: a randomized Phase III study of 1L ▼atezolizumab plus bevacizumab vs sorafenib in 1L Locally advanced or metastatic hepatocellular carcinoma

Efficacy and safety of ▼cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

Pharmacokinetic (PK) and exposure–response (ER) analysis of pertuzumab in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC)

Preliminary results from CECILIA, an open-label global safety study of bevacizumab, carboplatin, and paclitaxel therapy for metastatic, recurrent, or persistent cervical cancer

Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial

A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX)

Real-world data on tumor response in patients with advanced non-small-cell lung cancer receiving cancer immunotherapy or targeted therapies

Are NCCN Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small Cell Lung Cancer (aNSCLC)